Pharmaceuticals

Intercure

Intercure released FY2025 Q4 earnings on April 30 (EST), actual revenue USD 22 M, actual EPS USD -0.1037

Intercure released FY2025 Annual Earnings on April 30, 2026 (EST) with actual revenue of USD 79.92 M and EPS of USD -0.1952

Intercure released FY2025 Q3 earnings on April 30 EST, actual revenue USD 21.28 M, actual EPS USD -0.1003

Intercure released FY2025 9 Months Earnings on April 30 (EST), actual revenue USD 58.04 M, actual EPS USD -0.1088

Intercure released FY2025 Q2 earnings on October 8, 2025 (EST) with actual revenue of USD 19.18 M and EPS of USD -0.0044

Intercure released FY2025 Q1 earnings on October 8 (EST), actual revenue USD 17.58 M, actual EPS USD -0.004

Intercure released FY2025 Semi-Annual earnings on October 8 (EST), actual revenue USD 36.76 M, actual EPS USD -0.0084

Intercure released FY2024 Q3 earnings on May 1 (EST), actual revenue USD 15.17 M (forecast USD 22.87 M), actual EPS USD -0.2113 (forecast USD -0.098)

Intercure released FY2024 Q4 earnings on May 1 (EST), actual revenue USD 15.48 M (forecast USD 26.7 M), actual EPS USD -0.2157 (forecast USD -0.069)

Intercure released FY2024 Annual Earnings on May 1, 2025 (EST), actual revenue USD 64.36 M (forecast USD 88.75 M), actual EPS USD -0.3988 (forecast USD -0.392)

Intercure released FY2024 9-month earnings on May 1 (EST), actual revenue USD 48.86 M, actual EPS USD -0.2033

InterCure Ltd. Reports 2024 Fiscal Year Financial Performance and Expands Germany Partnership

InterCure Ltd. Delays Filing of Annual Report

InterCure Ltd. Reports Expanded Net Loss in 2024

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

INCR

InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow | INCR Stock News

StockTitan

InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow | INCR Stock News

ICCM

Extendicare Sets Date for Q1 2026 Results and Investor Call

Tip Ranks

Icecure Medical

iShares US Medical Devices

SPDR S&P Health Equip

Extendicare Sets Date for Q1 2026 Results and Investor Call

CUBT

CUBTD

Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care

Curative Biotechnology, Inc.

CURATIVE BIOTECHNOLOGY INC

Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care

InterCure Ltd. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive days. The company has until August 24, 2026, to regain compliance, potentially through a reverse share split. If compliance is not achieved, InterCure may face delisting. The company continues to trade on the Nasdaq Global Market and is committed to monitoring its share price and implementing strategies to restore compliance.

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement | INCR Stock News

InterCure reported preliminary 2025 results with estimated revenue of NIS 265 million, an 11% year-on-year increase, and positive adjusted EBITDA for the twelfth consecutive half-year. The company resumed operations at its Nir Oz facility, launched over 70 new GMP products, and began generating revenue in Germany. InterCure is advancing its expansion strategy by acquiring Botanico Ltd. and taking a stake in Cannasoul R&D. The latest analyst rating for InterCure stock is a Sell with a price target of ILs283.00.

InterCure Posts Higher 2025 Revenue and EBITDA, Resumes Nir Oz Output and Advances Expansion Plans

InterCure Ltd. (TLV:INCR) has seen its share price drop 29% in the last month and 49% over the past year, raising concerns among shareholders. The company's price-to-sales (P/S) ratio stands at 0.7x, significantly lower than the industry average of 2.7x, reflecting deteriorating revenue, which fell by 11% last year. With the industry expected to grow by 107% in the next year, InterCure's declining revenue trends suggest a challenging outlook, and the low P/S may not have reached its floor yet. Shareholders may face further risks as the company struggles to improve its financial performance.

Simplywall

Why Investors Shouldn't Be Surprised By InterCure Ltd.'s (TLV:INCR) 29% Share Price Plunge

Intercure rose 16.48%; Eli Lilly fell 0.42%, with a trading volume of USD 792 million; Johnson & Johnson rose 0.02%, with a trading volume of USD 370 million; Novo Nordisk rose 2.26%, with a trading volume of USD 244 million; AstraZeneca rose 0.13%, with a market value of USD 285.5 billion

Price Alert

U.S. stock market midday update: Intercure's stock price soared 16.48%, trading volume surged, and sector trends have attracted market attention?

Intercure(INCR.US)

InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow | INCR Stock News

Extendicare Sets Date for Q1 2026 Results and Investor Call

Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement | INCR Stock News

InterCure Posts Higher 2025 Revenue and EBITDA, Resumes Nir Oz Output and Advances Expansion Plans

Why Investors Shouldn't Be Surprised By InterCure Ltd.'s (TLV:INCR) 29% Share Price Plunge

U.S. stock market midday update: Intercure's stock price soared 16.48%, trading volume surged, and sector trends have attracted market attention?